A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058.
Advanced Malignant Tumour
DRUG: HRS-7058 capsule/ HRS-7058 tablet
Dose-limiting toxicity (DLT), From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months|maximum tolerated dose (MTD), From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months|Phase II recommended dose (RP2D), From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months|Safety endpoints: adverse events (AE), From the beginning of first patient in (FPI) to the end of study up to approximately 21 months]
Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion, From the beginning of first patient in (FPI) to the end of study up to approximately 21 months|Efficacy endpoints: duration of response (DoR) assessed based on RECIST v1.1 criterion, From the beginning of first patient in (FPI) to the end of study up to approximately 21 months|Efficacy endpoints: disease control rate (DCR) assessed based on RECIST v1.1 criterion, From the beginn ing of first patient in (FPI) to the end of study up to approximately 21 months|Efficacy endpoints: progression-free survival (PFS) assessed based on RECIST v1.1 criterion, From the beginn ing of first patient in (FPI) to the end of study up to approximately 21 months|Efficacy endpoints: overall survival (OS), From the beginn ing of first patient in (FPI) to the end of study up to approximately 21 months
This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058.